Synthesis of pregnane derivatives, their cytotoxicity on LNCaP and PC-3 cells, and screening on 5α-reductase inhibitory activity

Article abstract of DOI:10.3390/molecules14114655

A series of epoxy-and/or 20-oxime pregnanes were synthesized from commercially available pregnenolone. Compounds 1, 3, 7, 8 and 11-13 were evaluated for cytotoxicity activity towards LNCaP (androgen-dependent) and PC-3 (androgenindependent) prostate cancer cells. Compound 13 showed the highest activity on both LNCaP (IC₅₀ 15.17 μM) and PC-3 (IC₅₀ 11.83 μM) cell lines. Compound 11 showed weak activity on LNCaP cells (IC₅₀ 71.85 μM) and 8 showed the weak activity on PC-3 cells (IC₅₀ 68.95 μM), respectively. The 5α-reductase II (5AR2) inhibitory effects of compounds 1-3, 5 and 7-13 were investigated in a convenient screening model, in which compounds 5, 8, 11 and 12 were observed to be potential inhibitors of 5α-reductase, in particular, the 4-azasteroid 11, that also inhibited cell proliferation of androgen-dependent cells and 8, that in addition inhibited PC-3 cells more potently than LNCaP cells.

Full text of DOI:10.3390/molecules14114655

Molecules 2009, 14, 4655-4668; doi:10.3390/molecules14114655
OPEN ACCESS
molecules
ISSN 1420-3049
www.mdpi.com/journal/molecules
Article
Synthesis of Pregnane Derivatives, Their Cytotoxicity on LNCap
and PC-3 Cells, and Screening on 5α-Reductase Inhibitory
Activity
Sujeong Kim and Eunsook Ma *
College of Pharmacy, Catholic University of Daegu, Hayang, 712-702, Korea
* Author to whom correspondence should be addressed; E-Mail: masook@cu.ac.kr;
Tel.: +82-53-850-3621, Fax: +82-53-850-3602.
Received: 8 September 2009; in revised form: 4 November 2009 / Accepted: 8 November 2009 /
Published: 17 November 2009
Abstract: A series of epoxy- and/or 20-oxime pregnanes were synthesized from
commercially available pregnenolone. Compounds 1, 3, 7, 8 and 11-13 were evaluated for
cytotoxicity activity towards LNCaP (androgen-dependent) and PC-3 (androgen-
independent) prostate cancer cells. Compound 13 showed the highest activity on both
LNCaP (IC50 15.17 μM) and PC-3 (IC50 11.83 μM) cell lines. Compound 11 showed weak
activity on LNCaP cells (IC50 71.85 μM) and 8 showed the weak activity on PC-3 cells
(IC50 68.95 μM), respectively. The 5α-reductase II (5AR2) inhibitory effects of compounds
1-3, 5 and 7-13 were investigated in a convenient screening model, in which compounds 5,
8, 11 and 12 were observed to be potential inhibitors of 5α-reductase, in particular, the
4-azasteroid 11, that also inhibited cell proliferation of androgen-dependent cells and 8,
that in addition inhibited PC-3 cells more potently than LNCaP cells.
Keywords: 5α-reductase inhibitor; LNCaP; PC-3; epoxypregnanes; 20-oxime pregnanes
1. Introduction
Testosterone (T) and dihydrotestosterone (DHT) play a key role in the maintenance of cell
proliferation in the prostate gland. The enzyme steroid 5α-reductase (5AR) catalyzes the NADPH-
dependent reductive conversion of T to DHT. The deficiency of 5AR in males results in an incomplete
differentiation of external genitalia at birth [1]. On the other hand, abnormally high 5AR activity in

Molecules 2009, 14
4656
humans results in excessively high DHT levels in peripheral tissues, which is implicated in the
pathogenesis of prostate cancer, benign prostatic hyperplasia (BPH), acne and male pattern baldness
[2]. It is presently recognized that there are two genes encoding two distinct isozymes of 5AR that are
differentially expressed in human tissues and referred to as type 1 5AR (5AR1) and type 2 5AR
(5AR2) [3–5]. Although 5AR1 is predominantly expressed in the skin and liver, 5AR2 is mainly
expressed in prostate, seminal vesicles, liver and epididymis [6].
Various steroidal [7–9] and non-steroidal [10,11] inhibitors have been synthesized and tested
against 5AR. Of these, finasteride (PROSCAR®), a type II-selective 5α-reductase inhibitor, was the
first 5AR inhibitor approved in the USA for the treatment of BPH and prostate cancer. Finasteride was
also reported to reduce the proliferation rate in vitro of DU145 and PC-3 prostate cancer cell lines,
although several reports in the literature classified them as being “hormone-independent” [12].
Bologna reported that the growth rate of the LNCap cell line can be dose-dependently inhibited by a
5α-reductase inhibitor (finasteride) and antiandrogens (cuproterone and hydroxyflutamide) under
culture conditions with 5% FCS DMEM; on the other hand, growth of these cells is only modestly
stimulate by T and by DHT when those hormones are added under the same culture conditions [13].
However, finasteride is slow acting and produces side effects affecting sexual function [14,15]. It has
also been demonstrated that dutasteride acts as a 5AR1 and 5AR2 inhibitor and blocks the activation
of the androgen receptor with the consequences of decreased proliferation and increased death of
LNCaP cells [16], but is unresponsive on androgen-independent PC-3 cells [17].
Some steroidal 20-oximes were reported as dual inhibitors of P450 17 (17α-hydroxylase/C17,20-
lyase) and 5α-reductase [7,18]. 3-Acetoxy-5α,6α-epoxyprognan-16-ene-20-one, which doesn’t have a
double bond in the A or B rings [19], and 6α,7α-epoxy progesterone [8], showed a higher 5AR
inhibitory activity than finasteride. Some steroidal epoxy compounds have been used as important
intermediates to synthesize potent inhibitors of 5α-reductase, since their facile ring opening allows the
introduction of various functionalities in a stereospecific manner [20].
On the basis of the facts described in these references and in order to obtain the skeleton structure
required for 5AR inhibitory activity, we describe here the synthesis of some 20-oximes and/or epoxy
pregnane, pregnene and pregnadiene derivatives, their in-vitro cytotoxicity on LNCaP (androgen-
dependent) and PC-3 (androgen-independent) prostate cancer cells, and the screening test results as
potential inhibitors of 5AR2.
2. Results and Discussion
2.1. Synthesis of steroidal compounds
The synthesis of the eight 5,6-epoxy- and/or 20-oxime pregnane or pregnene derivatives is shown in
Scheme 1. Pregnenolone was reacted with m-chloroperoxybenzoic acid (mCPBA) to form 5α,6α-
epoxy-3β-hydroxypregnan-20-one (1). The α-epoxide stereochemistry of compound 1 was confirmed
by irradiation of H-6 (2.92 ppm), which showed a NOE to the C-19 methyl protons (1.06 ppm) in the
1D-NOESY spectrum. Compound 1 was quantitatively converted to the 20-oxime analog 2 using
hydroxylamine.

Molecules 2009, 14
4657
Scheme 1. Synthesis of 5,6-epoxy- and/or 20-oxime derivatives.
O
O
O
CH3
CH3
CH3
Ac2O
mCPBA
CHCl3, RT
24 h, 84%
H3PO4, RT
1 h, 85%
HO
AcO
HO
O
3
Pregnenolone
1
NH2OH
mCPBA
NH2OH
C2H5OH, Pyridine
Reflux, 2 h, 62%
CHCl3, RT
24 h, 53%
C2H5OH, Pyridine
Reflux, 2 h, 93%
HO-N
O
CH3
CH3
HO-N
CH3
AcO
AcO
O
HO
5
O
4a :
4b :
α−
β−
Epoxy
Epoxy
mCPBA
CHCl3, RT
48 h, 59%
2
HO-N
CH3
AcO
O
6a :
6b :
α−
β−
Epoxy
Epoxy
Pregnenolone was also further reacted with acetic anhydride to give 3β-acetoxy-5-pregnen-20-one
(3), which was reacted with mCPBA to afford a 1:1 mixture of 5α,6α- and 5β,6β-epoxy-3β-
acetoxypregnan-20-one (4a and 4b). The α- or β-configurations of the 5,6-epoxy group of 4a and 4b
were identified by irradiation of H-6 (3.10 and 2.91 ppm) which resulted in a NOE to the C-19 methyl
protons (1.08 ppm) in the 1D-NOESY spectrum. The 1D-NOESY spectrum showed that only H-6
(3.10 ppm) was correlated with the C-19 methyl protons. Consequently, this compound was
determined as 5α,6α-epoxy-3β-acetoxypregnan-20-one (4a) and the other H-6 proton (2.91 ppm) did
not show the correlation, it was identified as 5β,6β-epoxy compound 4b. Compound 3 was reacted
with hydroxylamine to give 3β-acetoxy-20-hydroxyimino-5-pregnen-20-one (5), which was reacted
with mCPBA to produce a mixture of 5α,6α- and 5β,6β-epoxy-3β-acetoxy-20-hydroxyiminopregnan-
20-ones (6a and 6b).
The synthesis of the 4-azasteroid 11 is shown in Scheme 2. Pregnenolone was reacted with
hydroxylamine to give 3β-hydroxy-20-hydroxyiminopregnenolone (7), which was oxidized with
aluminum isopropoxide in cyclohexanone to yield 20-hydroxyimino-4-pregnene-3,20-dione (8) by
Oppenauer oxidation. Compound 8 was oxidized with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone

Molecules 2009, 14
4658
(DDQ) to form 20-hydroxyimino-1,4-pregnadiene-3,20-dione (9) by a reported method [21]. Ring
cleavage of 8 by KMnO4 and NaIO4 gave 20-hydroxyimino-5-oxo-A-nor-3,5-secopregnan-3-oic acid
(10), which was cyclized with ammonium acetate to yield 4-aza-20-hydroxyimino-5-pregnene-3,20-
dione (11). The structure assignment of 10 was made by the disappearance of the double bond proton
1
(H-4) in the corresponding H-NMR spectrum and by the appearance of two carbonyl carbons (214.7
and 209.2 ppm) in the 13C-NMR spectrum. 4-Azasteroid 11 was identified by observing a double bond
1
proton (H-6, 4.82 ppm) and an NH proton (7.41 ppm) in the H-NMR spectrum and one carbonyl
carbon (209.3 ppm) in the 13C-NMR spectrum. 1,4,6-Pregnatriene-3,17-dione (12) was synthesized
from pregnenolone with DDQ and then reacted with 30% H2O2 in 5% NaOH-MeOH to give 1α,2α-
epoxy-4,6-pregnadiene-3,17-dione (13), stereoselectively. The α-epoxy configuration of the 1,2-epoxy
group in 13 was determined from the 1D-NOESY spectrum, where irradiation of the H-1 proton (4.16
ppm) showed an NOE to 19-CH3 (1.19 ppm).
Scheme 2. Synthesis of 4-azasteroid 11 and unsaturated steroid derivatives.
HON
HON
HON
CH3
DDQ
CH3
Al(O-iPr)3
CH3
NH2OH,Ethanol
Pyridine,Reflux
1 h, 95%
Cyclohexanone
Reflux, 4h, 46%
1,4-Dioxane
Reflux, 4h,49%
Pregnenolone
O
HO
O
8
9
7
DDQ
1,4-Dioxane
Reflux, 4h,49%
HON
O
HON
CH3
CH3
CH3
NH4COOCH3
Acetic acid
Reflux, 1 h, 50%
O
N
H
O
O
O
12
OH
H2O2
5% NaOH-MeOH
Methanol
11
10
RT, 5 h, 68%
O
CH3
O
O
13
2.2. MTT test
Human prostate carcinoma cell lines have been available since 1977 and represent a good
experimental model to assess new hormonal therapies [12]. Charcoal stripped-dextran treated heat
inactivated 10% FBS was used for these assays to remove the endogeneous steroids.
We assessed the cytotoxicity of synthesized compounds 1, 3, 7, 8 and 11-13 on LNCap (androgen-
dependent) and PC-3 (androgen-independent) cancer cells. (Figures 1 and 2) As shown in Figure 1, the
4-azasteroid 11 showed a dose dependently inhibitory effect on LNCaP cell and also exerted a higher
cytotoxicity effect than finasteride, but 8 inversely inhibited the cell proliferation of PC-3 cell. 1,2-
Epoxy compound 13 showed the highest cytotoxicity on both LNCaP (IC50 15.17 μM) and PC-3 (IC50
11.83 μM) cells. (Table 1) We thought that the cytotoxicity ability of 13 was due to epoxy ring
especially on 1,2-position of steroid structure independent of cell type.

Molecules 2009, 14
Figure 1. Cytotoxicity of F (finasteride) and 1, 3, 7, 8, 11-13 on LNCaP cells.
4659
Figure 2. Cytotoxicity of F (finasteride) and 1, 3, 7, 8, 11-13 on PC-3 cells.

Molecules 2009, 14
Table 1. The IC50 values of synthesized compounds on LNCaP and PC-3 cells.
4660
LNCaP cell
IC50 (μM)
>100
PC-3 cell
IC50 (μM)
>100
Compound No.
Finasteride
1
3
>100
>100
>100
>100
7
>100
>100
8
>100
68.95
11
12
13
71.85
>100
15.17
>100
>100
11.83
2.3. Screening test of 5α-reductase II inhibitory activity
This purpose of this experiment is to obtain preliminary data on the 5AR2 inhibitory activity of the
synthetic compounds. Jang et al. [22] reported that the HEK293 cells were stably transfected with
5AR2 and they suggested RT-PCR data to validate that the stable transfection has been achieved. They
determined that 10 μg of stable cell extract completely converted 1 μCi of T into DHT in an in vitro
enzymatic assay. We used this convenient screening method to observe the 5α-reductase inhibitory
activities of compounds 1, 2, 3, 5 and 7-13. As shown in Figure 3, 3β-acetoxy-20-hydroxyimino-5-
pregnen-20-one (5), 20-hydroxyimino-5-pregnen-20-one (8), 4-aza-20-hydroxyimino-5-pregnene-
3,20-dione (11) and 1,4,6-pregnatriene-3,20-dione (12) showed potential 5α-reductase inhibitory
activity. None of the 3-hydroxy pregnene and pregnadiene derivatives showed any inhibitory activity.
The inhibitory mechanism of enone compounds 8 and 12 towards the enzyme 5α-reductase can be
generally explained by the fact that 5AR forms an enzyme-steroid activated complex in the first step
and the nucleophilic portion of the enzyme attacks their double bond instead of testosterone in a
Michael type addition reaction and NADPH subsequently donates a hydrogen to the C-5 position of
the compounds [1]. It is assumed that the carbonyl group of the 3-acetoxy substituent of 5 and the
3-carbonyl group of 11 bind to the enzyme and then next step is same as that of the enones. However
all tested compounds showed lower activity than finasteride, therefore a substituent at the C-20
position more bulky than an oxime group seems to be required. Consequently, the carbonyl group at
the C-3 position, a substituted oxime at the C-20 position and an unsaturated bond in the A and/or B
rings of the pregnane skeleton seem to be important for 5α-reductase inhibitory activity. Compound 8
is more active than the 4-azasteride analog 11, consequently we don’t think that 4-azasteride is a
necessary feature for activity. Compound 11 also showed cytotoxicity on androgen-dependent LNCaP
cells, therefore the cytotoxicity of this compound was seems to relate with the androgens.

Molecules 2009, 14
Figure 3. Data of type II 5α-reductase inhibitory activity of finasteride (a) and synthetic
4661
compounds (b). Ten micrograms of stable cell extracts was incubated with 1 μCi
[3H]testosterone and synthetic compounds (1 μM and 10 μM) for 1 hr. T, testosterone;
DHT, 5α-dihydrotestosterone.
(a)
DHT
T
T
CT 1000 500 250 125 62 31 15 (nM)
(b)
DHT
T
T CTL 10
1
10
1
10
1
10
1
10 1 (uM)
1
2
3
5
7
DHT
T
10 1 10
1
10
1
10
1
10
1
10 1 (uM)
8
9
10
11
12
13
3. Experimental
3.1. General
All non-aqueous reactions were performed under a dry atmosphere of nitrogen. The commercial
reagents were purchased from Aldrich, Fluka, or Sigma. Solvents were purified and dried prior to use.
13
Melting points was measured on Thomas-Hoover melting point apparatus and not corrected. 1H-, C-
NMR and NOESY spectra were taken on a Varian 400 MHz spectrometer in DMSO-d6, D2O or
CDCl3. Chemical shifts (δ) are in parts per million (ppm) relative to tetramethylsilane, and coupling
constants (J) are in Hertz. IR spectra were determined on a Jasco FT-IR 300E spectrometer as KBr
pellets. GC/MS spectra were obtained on Shimadzu QP 5050 and JEOL GC Mate 2 mass spectrometer.
MPLC was performed on Yamazen YFLC-AI and an analytical TLC was performed on pre-coated
silica gel 60 F254 plates (Merck). Solvent systems for TLC were ethyl acetate/n-hexane mixtures and
10% MeOH in methylene chloride. Column chromatography was carried out on Merck silica gel 9385
(230-400 mesh) and eluted with ethyl acetate/n-hexane mixtures.
5α,6α-Epoxy-3β-hydroxypregnan-20-one (1): 5-Pregnen-3β-ol-20-one (500 mg, 1.58 mmol) and
mCPBA (818.0 mg, 4.74 mmol) were dissolved in chloroform (50 mL) and stirred at room temperature

Molecules 2009, 14
4662
for 24 hours. The reaction mixture was diluted with H2O and washed with aqueous FeSO4, saturated
NaHCO3, H2O and the aqueous layer extracted with dichloromethane. The organic layer was dried
with anhydrous MgSO4, filtered and evaporated to give the crude compound, which was purified by
column chromatography (ethyl acetate/n-hexane = 1:1) to give 440 mg (84%) of the pure white
product 1. m.p : 176-179 °C, 1H-NMR (CDCl3) δ: 3.87-3.96 (1H, m, 3-H), 2.92 (1H, d, J = 4.4 Hz, 6-
H), 2.50 (1H, t, J = 8.8 Hz, 17-H), 2.11 (3H, s, 21-CH3), 1.06 (3H, s, 19-CH3), 0.56 (3H, s, 18-CH3);
13C-NMR (CDCl3) δ: 209.5 (20-C=O), 68.6 (5-C), 65.7 (3-C), 63.4 (17-C), 59.1 (6-C), 57.0, 43.9,
42.5, 39.8, 38.5, 34.9, 32.4, 31.6, 31.0, 29.9, 28.7, 24.2, 22.7, 20.7, 15.9, 13.2; GC-mass (EI) m/z : 332
(M)+, 314 (M+1-H2O)+; IR (cm-1): 3441 (3-O-H), 1702 (20-C=O).
5α,6α-Epoxy-3β-hydroxy-20-hydroxyiminopregnan-20-one (2): Compound 1 (300 mg, 0.90 mmol) was
dissolved in ethanol (5 mL) and hydroxylamine hydrochloride (100.8 mg, 1.44 mmol) and pyridine
(0.15 mL) were added and the mixture was refluxed at 130 °C for 2 hours. The reaction mixture was
diluted with H2O and extracted with dichloromethane. The organic layer was dried with anhydrous
MgSO4, filtered, and evaporated to give crude product, which was recrystallized with ethyl acetate and
1
n-hexane to give 290 mg (93%) of the pure white product 2, m.p : 144-147 °C, H-NMR (DMSO-d6)
δ: 10.35 (1H, s,=NOH), 4.55 (1H, br s, 3-OH), 3.91 (1H, d, J = 2.4 Hz, 6-H), 3.77-3.81 (1H, m, 3-H),
13
1.72 (3H, s, 21-CH3), 1.13 (3H, s, 19-CH3), 0.55 (3H, s, 18-CH3); C-NMR (DMSO-d6) δ:155.8 (20-
C=NOH), 75.2 (5-C), 66.2 (3-C), 65.3 (6-C), 56.8 (17-C), 55.0, 45.1, 44.0, 41.9, 39.2, 39.0, 35.8, 33.2,
31.5, 30.8, 24.4, 23.3, 21.3, 18.5, 15.9, 13.9; GC-mass (EI) m/z : 348 (M+1)+, 330 (M+1-H2O)+; IR
(cm-1) : 3401 (O-H), 1640 (C=N).
3β-Acetoxy-5-pregnen-20-one (3): 5-Pregnen-3β-ol-20-one (pregnenolone, 1 g, 3.16 mmol) was
dissolved in acetic anhydride (20 mL) and phosphoric acid. The reaction mixture was stirred for 1 hour
at room temperature and evaporated to remove acetic anhydride to give crude oily product, which was
diluted with H2O. The reaction mixture was neutralized with saturated NaHCO3 (aq.) and extracted
with dichloromethane. The organic layer was dried with anhydrous MgSO4, filtered, and evaporated to
give crude product, which was purified by column chromatography (ethyl acetate/n-hexane = 1:1) to
give 960 mg (85%) of pure white product 3, m.p : 147-149 °C,1H-NMR (CDCl3) δ: 5.38 (1H, d,
J = 4.8 Hz, 6-H), 4.56-4.65 (1H, m, 3-H), 2.54 (1H, t, J = 9.0 Hz, 17-H), 2.13 (3H, s, 21-CH3), 2.04
(3H, s, -COCH3), 1.02 (3H, s, 19-CH3), 0.63 (3H, s, 18-CH3); 13C-NMR (CDCl3) δ : 209.6 (20-C=O),
170.6 (3-OCOCH3), 139.7 (5-C), 122.3 (6-C), 73.8 (3-C), 63.7 (17-C), 56.8, 49.9, 44.0, 38.8, 38.1,
37.0, 36.6, 31.8, 31.7, 31.6, 27.7, 24.5, 22.8, 21.4, 21.0, 19.3, 13.2, GC-mass (EI) m/z: 359 (M+1)+,
298 (M-CH3COOH +, IR (cm-1) : 1728 (20-C=O), 1704 (3-C=O).
3β-Acetoxy-5α,6α-epoxypregnan-20-one (4a) and 3β-acetoxy-5β,6β-epoxypregnan-20-one (4b): 3β-
Acetoxy-5-pregnen-20-one (3, 100 mg, 0.28 mmol) and mCPBA (145 mg, 0.84 mmol) were dissolved
in chloroform (10 mL) and the reaction mixture was stirred at room temperature for 24 hours. The
reaction mixture was treated as the same method of compound 1. The crude compound was purified by
column chromatography (ethyl acetate/n-hexane = 1:5), giving 56 mg (53%) of a mixture of 4a and 4b.
Compound 4a: 1H-NMR (CDCl3) δ: 4.90-5.00 (1H, m, 3-H), 3.10 (1H, d, J = 1.8 Hz, 6-H), 2.09 (3H, s,
21-CH3), 2.01 (3H, s, 3-COCH3), 1.01 (3H, s, H-19), 0.57 (3H, s, 18-CH3), 13C-NMR (CDCl3) δ: 208.4

Molecules 2009, 14
4663
(20-C=O), 170.9 (3-OCOCH3), 71.3 (5-C), 63.4 (3-C), 56.6 (6-C), 56.2 (17-C), 50.9, 42.4, 38.0, 36.7,
1
36.1, 32.4, 32.1, 29.7, 27.2, 24.4, 22.8, 22.7, 21.9, 21.3, 20.6, 13.2, 13.1; Compound 4b: H-NMR
(CDCl3) δ: 4.72-4.82 (1H, m, 3-H), 2.91 (1H, d, J = 3.6 Hz, 6-H), 2.10 (3H, s, 3-COCH3), 2.03 (3H, s,
21-CH3), 1.08 (3H, s, H-19), 0.60 (3H, s, 18-CH3); 13C-NMR (CDCl3) δ: 208.4 (20-C=O), 170.8
(3-OCOCH3), 71.4 (5-C), 63.3 (3-C), 56.7 (6-C), 56.2 (17-C), 50.9, 42.4, 38.0, 36.7, 36.1, 32.4, 32.1,
29.7, 27.2, 24.4, 22.8, 22.7, 21.9, 21.3, 20.6, 13.2, 13.1, GC-mass (EI) m/z : 374 (M)+, IR (cm-1) : 3441
(3-O-H), 1702 (20-C=O).
3β-Acetoxy-20-hydroxyimino-5-pregnen-20-one (5): 3β-Acetoxy-5-pregnen-20-one (3, 100 mg, 0.28
mg) was dissolved in ethanol (2 mL), hydroxylamine hydrochloride (31.3 mg, 0.45 mmol) and
pyridine (0.1 mL) and the reaction mixture was refluxed for 2 hours at 130 ℃. The reaction mixture
was poured into cold water (30 mL) to form a precipitate, which was recrystallized with ethyl acetate
and n-hexane to afford 65 mg (62%) as the pure white product 5, m.p: 201-205 °C, 1H-NMR (CDCl3)
δ: 8.28 (1H, s, =NOH), 5.38 (1H, d, J = 5.2 Hz, 6-H), 4.56-4.67 (1H, m, 3-H), 2.04 (3H, s, -COCH3),
1.89 (3H, s, 21-CH3), 1.02 (3H, s, 19-CH3), 0.65 (3H, s, 18-CH3); 13C-NMR (CDCl3) δ: 170.6
(3-OCOCH3), 158.9 (20-C=NOH), 139.7 (5-C), 122.4 (6-C), 73.9 (3-C), 56.8 (17-C), 56.1, 50.1, 43.8,
38.7, 38.1, 37.0, 36.6, 36.5, 32.0, 31.8, 27.8, 24.2, 23.1, 21.4, 21.0, 19.3, 15.1, 13.1; GC-mass (EI) m/z:
342 (M-NOH)+, 313 (M-CH3COOH)+; IR (cm-1) : 3315 (20-C=NOH), 1732 (3-OC=OCH3), 1651 (20-
C=N).
3β-Acetoxy-5α,6α-epoxy-20-hydroxyiminopregnan-20-one (6a) and 3β-acetoxy-5β,6β-epoxy-20-
hydroxyiminopregnan-20-one (6b): 3β-Acetoxy-20-hydroxyimino-5-pregnen-20-one (5, 100 mg, 0.27
mmol) and mCPBA (139 mg, 0.81 mmol) were dissolved in chloroform (10 mL) and stirred at room
temperature for 48 hours. The reaction mixture was treated as the same method of compound 1. The
crude compound was purified by column chromatography (ethyl acetate/n-hexane = 1:3) and gave 62
mg (59%) as a mixture of 6a and 6b. Compound 6a: 1H-NMR (CDCl3) δ: 4.91-4.97 (1H, m, 3-H), 3.09
(1H, d, J = 2.0 Hz, 6-H), 2.02 (3H, s, -COCH3), 1.86 (3H, s, 21-CH3), 1.01 (3H, s, 19-CH3), 0.57 (3H,
s, 18-CH3); 13C-NMR (CDCl3) δ: 170.6 (3-OCOCH3), 158.8 (20-C=NOH), 71.8 (5-C), 63.0 (3-C),
56.7 (6-C), 56.1 (17-C), 50.4, 43.1, 40.2, 39.0, 38.3, 37.6, 36.1, 35.3, 31.8, 29.7, 24.2, 22.6, 23.4, 21.3,
19.5, 15.4. Compound 6b: 1H-NMR (CDCl3) δ: 4.87-4.96 (1H, m, 3-H), 2.92 (1H, d, J = 4.4 Hz, 6-H),
13
2.03 (3H, s, -COCH3), 1.86 (3H, s, 21-CH3), 1.08 (3H, s, 19-CH3), 0.60 (3H, s, 18-CH3); C-NMR
(CDCl3) δ: 170.5 (3-OCOCH3), 158.8 (20-C=NOH), 71.9 (5-C), 63.1 (3-C), 56.5 (6-C), 56.1 (17-C),
50.4, 43.1, 40.2, 39.0, 38.3, 37.6, 36.1, 35.3, 31.8, 29.7, 24.2, 22.6, 23.4, 21.3, 19.5, 15.4, 13.1; GC-
mass (EI) m/z: 358 (M-NOH)+, 329 (M-CH3COOH)+; IR (cm-1): 3441 (3-O-H), 1702 (20-C=O).
3β-Hydroxy-20-hydroxyimino-5-pregnen-20-one (7): To a solution of 5-pregnen-3β-ol-20-one (1 g,
3.16 mmol) in ethanol (15 mL) was added hydroxylamine hydrochloride (352 mg, 5.06 mmol) and
pyridine (0.5 mL) and the reaction mixture was refluxed at 130 °C for 1 hour. The reaction mixture
was cooled down and extracted with dichloromethane and the organic layer was washed with H2O,
dried with anhydrous MgSO4, filtered and concentrated to afford crude oily material. The crude
product was purified by column chromatography (ethyl acetate/n-hexane = 1:3) affording 1.0 g (95%)

Molecules 2009, 14
4664
as the pure white product 7, m.p : 220-222 °C, 1H-NMR (CDCl3) δ : 7.80 (1H, s, = NOH), 5.36 (1H, t,
J = 2.6 Hz, 6-H), 3.50-3.56 (1H, m, 3-H), 1.89 (3H, s, 21-CH3), 1.01 (3H, s, 19-CH3), 0.65 (3H, s,
18-CH3); 13C-NMR (CDCl3) δ: 159.0 (20-C=NOH), 140.8 (5-C), 121.5 (6-C), 71.8 (3-C), 56.7 (17-C),
56.2, 50.1, 43.8, 42.3, 38.7, 37.3, 36.5, 32.0, 31.8, 31.6, 24.2, 23.1, 21.0, 19.4, 15.1, 13.1; GC-mass
(EI) m/z: 331 (M)+, 316 (M-CH3)+, 298 (M+-CH3-H2O); IR (cm-1): 3239 (O-H) 1662 (20-C=N).
20-Hydroxyimino-4-pregnene-3,20-dione (8): The mixture of compound 7 (1 g, 3.01 mmol), aluminum
isopropoxide (3 g, 15 mmol) and cyclohexanone (30 mL) was refluxed at 170 °C for 4 hours. The
excess of cyclohexanone was distilled off and the residue was added H2O and acidified with 5 M HCl
and extracted with ethyl acetate. The organic layer was dried with anhydrous MgSO4, filtered and
evaporated to give crude oil, which was purified by column chromatography (ethyl acetate:n-hexane =
1
1:3) to yield 460 mg (46%) of the pure pale yellow product 8, m.p: 213-216 °C, H-NMR (CDCl3) δ:
8.14 (1H, s,=NOH), 5.74 (1H, s, 4-H), 1.89 (3H, s, 21-CH3), 1.18 (3H, s, 19-CH3), 0.68 (3H, s,
18-CH3); 13C-NMR (CDCl3) δ: 199.6 (3-C=O), 171.3 (20-C=NOH), 158.7 (5-C), 123.9 (4-C), 56.6
(17-C), 55.3, 53.8, 43.8, 38.6, 38.5, 35.8, 35.7, 34.0, 32.8, 31.9, 24.1, 23.0, 21.0, 17.4, 15.1, 13.2; GC-
mass (EI) m/z: 329 (M)+, 312 (M-OH)+; IR (cm-1): 3498 (20-C=NOH), 1658 (3-C=O), 1614 (20-C=N).
20-Hydroxyimino-1,4-pregnadiene-3,20-dione (9): To a solution of compound 8 (200 mg, 0.6 mmol) in
1,4-dioxane (12 mL) was added DDQ (272 mg, 1.20 mmol), bis(trimethylsilyl)trifluoroacetamide
(0.3 mL) and the reaction mixture was refluxed at 150 °C for 12 hours. The reaction mixture was
filtered, concentrated and the crude product was purified by column chromatography (ethyl acetate/n-
1
hexane = 1:3) to yield 96 mg (49%) of the pure white product 9. m.p: 105-110 °C, H-NMR (CDCl3)
δ: 7.06 (1H, d, J = 10.4 Hz, 1-H), 6.24 (1H, dd, J1 = 1.8 Hz, J2 = 10.2 Hz, 2-H), 6.08 (1H, s, 4-H), 2.52
(1H, t, J = 9.0 Hz, 17-H), 2.12 (3H, s, 21-CH3), 1.24 (3H, s, 19-CH3), 0.70 (3H, s, 18-CH3); 13C-NMR
(CDCl3) δ : 209.2 (20-C=O), 186.3 (3-C=O), 168.9 (5-C), 155.6 (1-C), 127.6 (2-C), 124.0 (4-C), 63.4
(17-C), 55.6, 52.2, 44.1, 43.5, 38.5, 35.5, 33.5, 32.8, 31.5, 24.6, 22.84, 22.82, 18.7, 13.4; GC-Mass
(EI) m/z: 327 (M)+; IR (cm-1): 3315 (20-C=NOH), 1662 (3-C=O), 1619 (20-C=N).
20-Hydroxyimino-5-oxo-A-nor-3,5-secopregnan-3-oic acid (10): 20-Hydroxyimino-4-pregnene-3,20-
dione (8, 250 mg, 0.76 mmol) was dissolved in tert-butanol (5 mL) and anhydrous sodium carbonate
(118 mg, 1.11 mmol), H2O (2 mL) was added and refluxed at 180 °C. Sodium periodate (1 g, 5.32
mmol) and potassium permanganate (15 mg, 0.09 mmol) dissolved in H2O (5 mL) was slowly added to
a refluxing reaction mixture, and refluxed for 3 hours. The mixture was filtered and washed with H2O
and the filtrate was acidified with 5 M HCl and extracted with dichloromethane. The organic layer was
dried with anhydrous MgSO4, filtered and concentrated to give crude product, which was purified by
column chromatography (methanol: dichloromethane = 1:9) to yield 154 mg (58%) of the pure pale
yellow product 10. m.p: 152-155 °C, 1H-NMR (CDCl3) δ: 2.57 (1H, t, J = 8.2 Hz, 17-H), 2.13 (3H, s,
13
21-CH3), 1.13 (3H, s, 19-CH3), 0.69 (3H, s, 18-CH3); C-NMR (CDCl3) δ: 214.7 (5-C=O), 209.2 (3-
COOH), 177.8 (20-C=NOH), 63.4 (17-C), 55.9, 50.4, 47.9, 44.0, 38.4, 38.0, 34.9, 31.5, 31.2, 29.3,
29.0, 24.4, 22.8, 21.5, 20.3, 13.4; GC-Mass (EI) m/z: 349 (M)+, 332 (M-H2O) +; IR (cm-1): 3445 (O-H),
1702 (C=O), 1651 (20-C=N).

Molecules 2009, 14
4665
4-Aza-20-hydroxyimino-5-pregnene-3,20-dione (11): A mixture of 20-hydroxyimino-4-pregnen-3-one
(10, 65 mg, 0.18 mmol), ammonium acetate (42 mg, 0.54 mmol) and acetic acid (2 mL) was refluxed
for 1 hour. The mixture was evaporated to remove acetic acid and the residue was neutralized with
saturated NaHCO3 and extracted with dichloromethane. The organic layer was dried with anhydrous
MgSO4, filtered and concentrated to give crude pale-brown solid, which was recrystallized with ethyl
acetate and n-hexane and eluted 30 mg (50%) as the pure white product 11. m.p: 225-227 °C, 1H-NMR
(CDCl3) δ: 7.41 (1H, s, -NH), 4.82 (1H, dd, J1 = 2.2 Hz, J2 = 5.0 Hz, 6-H), 2.55 (1H, t, J = 8.0 Hz,
13
17-H), 2.14 (3H, s, 21-CH3), 1.10 (3H, s, 19-CH3), 0.66 (3H, s, 18-CH3); C-NMR (CDCl3) δ: 209.4
(3-C=O), 169.3(20-C=NOH), 140.0 (5-C), 103.0 (6-C), 63.5 (17-C), 56.6, 47.8, 44.0, 38.5, 34.3, 31.8,
31.6, 31.5, 29.6, 28.4, 24.4, 22.8, 21.0, 18.7, 13.3; GC-Mass (EI) m/z: 330 (M)+, 315 (M-NH)+, 300
(M++1-NOH); IR (cm-1): 3187 (20-C=NOH), 3071 (N-H), 1669 (3-C=O).
1,4,6-Pregnatriene-3,20-dione (12): To a mixture of 5-pregnen-3β-ol-20-one (3 g, 9.46 mmol) in 1,4-
dioxane (40 mL) was added DDQ (8.6 g, 37.90 mmol) at room temperature and the mixture was
refluxed for 4 hours. The reaction mixture was cooled down and filtered, washed with 1,4-dioxane and
concentrated to give crude product, which was purified by column chromatography (ethyl acetate/n-
hexane = 1:3) to yield 2 g (70%) of the pure white product 12. m.p: 145-147 °C (lit. [23] 142-144 °C).
1,2-Epoxy-4,6-pregnadiene-3,20-dione (13): A mixture of 1,4,6-pregnatriene-3,20-dione (12, 500 mg,
1.61 mmol) in methanol (25 mL) was slowly added 30% hydrogen peroxide (4.5 mL) and 5% NaOH-
MeOH (1.2 mL) and stirred at room temperature for 5 hours. The reaction mixture was mixed with
H2O (5 mL) and concentrated to form the crude precipitate, which was recrystallized with methanol
1
and H2O to give 360 mg (68%), of a white product, m.p: 184-187 °C, H-NMR (CDCl3) δ: 6.12 (1H,
dd, J1 = 2.8 Hz, J2 = 10.0 Hz, 7-H), 6.05 (1H, d, J = 10.8 Hz, 6-H), 5.67 (1H, s, 4-H), 3.60 (1H, d, J =
4.0 Hz, 2-H), 3.46-3.47 (1H, m, 1-H), 2.60 (1H, t, J = 9.4 Hz, 17-H), 2.15 (3H, s, 21-CH3), 1.19 (3H, s,
13
19-CH3), 0.74 (3H, s, 18-CH3); C-NMR (CDCl3) δ : 209.0 (20-C=O), 194.6 (3-C=O), 158.5 (5-C),
139.6 (7-C), 128.1 (6-C), 119.7 (4-C), 63.1 (17-C), 59.4 (2-C), 54.7 (1-C), 53.5, 45.9, 44.3, 38.8, 38.3,
37.4, 31.6, 23.9, 22.9, 21.2, 18.5, 13.2; GC-mass (EI) m/z: 326 (M)+; IR (cm-1): 1700 (20-C=O), 1662
(3-C=O).
3.2. Biology
We purchased LNCaP (androgen receptor dependent cell line) and PC-3 (androgen receptor
independent cell line) prostate cancer cells from the Korean Cell Line Bank (Seoul). Finasteride was
purchased from Aldrich Co and was used as positive control. RPMI medium 1640, fetal bovine serum
(FBS, Gibco), penicillin-streptomycin, phosphate buffered saline (PBS) pH 7.4, 0.25% trypsin EDTA,
dimethyl sulfoxide (DMSO, Sigma), thiazolyl blue tetrazolium bromide (MTT, Sigma) and finasteride
(Sigma) were purchased.
3.2.1. MTT assay on LNCaP and PC-3 cell
LNCaP and PC-3 prostate cancer cells were grown in RPMI medium 1640 containing charcoal
stripped-dextran treated heat inactivated 10% fetal bovine serum (FBS) (Gibco BRL, Rockville, MD,

Molecules 2009, 14
4666
USA) supplemented with 1% penicillin-streptomycin. Cells (2 × 103) were planted in 96 well cell
plates and incubated in 5% CO2 incubator (NAPCO Water-Jacketed CO2 incubator) for 24 hours at
37 °C. Then cells were treated with 0, 1, 5, 10, 20, 50, 100 μM concentrations of sample (5 μL/well)
and incubated in 5% CO2 incubator for 48 hours at 37 °C. Triplicate wells were used for each
concentration. After incubation for 48 hours, 50 μL/well of MTT (2 mg/mL in PBS) was added and
further incubated for four hours in the dark. After removal of MTT solution, 150 μL/well DMSO was
added to dissolve purple crystal for 15 minutes, after which the absorbance of the solution was
measured at 540 nm with an ELISA reader (ELx 808, BIO-TEK). The inhibition effect of LNCaP and
PC-3 cell growth was expressed relative cell survival percentage.
3.2.2. Screening assay for type II 5α-reductase inhibitory activity
According to the method reported [22], human embryonic kidney cells (HEK293) over-expressing
type II 5α-reductase were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% FBS. Stable HEK293 cells (1 × 106) were planted in 24-well cell plate and incubated in 5% CO2
incubator for 24 hours at 37 °C. Stable cells were suspended in 50 mM sodium phosphate buffer (pH
5.5) and lysed by sonication for 1 min. The reaction mixture for type II 5-reductase contained 10 μL
(10 μg total protein) of cell extract, 65 μL of reaction buffer [60 mM sodium phosphate, pH 5.5, 50
mM KCl, 1 mM NADPH, and 1 μCi [1,2,6,7-3H]testosterone (65.0 Ci/mmol, Amersham)], and 1 μM
and 10 μM of synthesized compounds. The reaction mixtures were incubated at 37 °C for 1 h, followed
by steroids extraction with 250 μL of stop solution (70% cyclohexane, 30% ethyl acetate, 40 μg/mL T
and 40 μg/mL DHT). Solvent was dried and steroids were dissolved with 20 μL of chloroform, spotted
onto thin layer chromatography (TLC) plate (Merck, Darmastadt, Germany) and developed in 80%
3
toluene, 20% acetone. TLC plate was then exposed to Hyperfilm H (Amersham, RPN 535B) for
three days.
3.3. Statistical analysis
Triplicate analyses were performed for MTT test and all the data were subjected to analysis of
variance using ANOVA and Duncan’s multiple range test for significant difference comparison.
4. Conclusions
Thirteen epoxy- and/or 20-oxime pregnane, pregnene and pregnadiene derivatives were synthesized
and evaluated for cytotoxicity activity and 5AR2 inhibition effects. The 5AR2 inhibition screening test
results suggested that compounds 5, 8, 11 and 12 were potential inhibitors of 5α-reductase type II.
Especially, 11 was active in the 5AR2 inhibitory test, and inhibited cell proliferation of androgen-
dependent cell and 8 was the most active in the 5AR2 inhibitory test, but interestingly, it inhibited PC-
3 cells more potently than LNCaP cells. Compound 13 showed the highest cytotoxic effects on both
LNCap and PC-3 prostate cancer cells.
Acknowedgements
Financial support from Catholic University of Daegu is gratefully acknowledged.

Molecules 2009, 14
4667
References
1. Abul-Hajj, Y.J. Stereospecificity of hydrogen transfer from NADPH by steroid ∆4-5α-and ∆4-5β-
reductase. Steroids 1972, 20, 215–222.
2. Cabeza, M.; Flores, E.; Heuze, I.; Sanchez, M.; Bratoeff, E.; Ramirez, E.; Francolugo, V.A. Novel
17-substituted pregnadiene derivatives as 5α-reductase inhibitors and their binding affinity for the
androgen receptor. Chem. Pharm. Bull. 2004, 52, 535–539.
3. Andersson, S.R.; Bishop, R.W.; Russell, D.W. Expression cloning and regulation of steroid 5α-
reductase, an enzyme essential for male sexual differentiation. J. Biol. Chem. 1989, 264, 16249–
16255.
4. Andersson, S.; Russell, D.W. Structural and biochemical properties of cloned expressed human
and rat steroid 5α-reductase. Proc. Natl. Acad. Sci. USA 1990, 87, 3640–3644.
5. Russell, D.W.; Wilson, J.D. Steroid 5alpha-reductase: Two genes/two enzymes. Ann. Rev.
Biochem. 1994, 63, 25–61.
6. Thigpen, A.E.; Silver, R.I.; Guileyardo, J.M.; Casey, M.; McConnel. J.D.; Russell, D.W. Tissue
distribution and ontogeny of steroid 5alpha-reductase isozyme expression. J. Clin. Invest. 1993,
92, 903–910.
7. Hartmann, R.W.; Hector, M.; Haidar, S.; Ehmer, P.B.; Reichert, W.; Jose, J. Synthesis and
evaluation of novel steroidal oxime inhibitors of P450 17 (17α-hydroxylase/C17,20-lyase) and
5 -reductase types 1 and 2. J. Med. Chem. 2000, 43, 4266–4277.
8. Ramírez, E.; Cabeza, M.; Heuze, I.; Gutierrez, E.; Bratoeff, E.; Membrillo, M.; Lira, A. Synthesis
and pharmacological evaluation of new 16-methyl pregnenolone derivatives. Chem. Pharm. Bull.
2002, 50, 15–20.
10. Audia, J.E.; Lawhorn, D.E.; Deeter, J.B. Synthesis of the individual enantiomers of the
benzoquinolinone human type 1 steroid 5α-reductase inhibitors LY191704 and LY266111.
Tetrahedron Lett. 1993, 34, 7001–7004.
11. Bologna, M.; Muzi, P.; Biordi, L.; Festuccia, C.; Vicentini, C. Antiandrons and 5alpha-
reductaseinhibition of the proliferation rate in PC 3 and DU 145 human prostatic cancer cell lines.
Curr. Ther. Res. 1991, 51, 799–813.
11. Jones, C.D.; Audia, J.E.; Lawhorn, D.E.; McQuaid, L.A.; Neubauer, B.L.; Pike, A.J.; Pennington,
P.A.; Stamm, N.B.; Toomey, R.E.; Hirsch, K.S. Nonsteroidal inhibitors of human type I steroid
5α-reductase. J. Med. Chem. 1993, 36, 421–423.
12. Bologna, M.; Muzi, P.; Biordi, L.; Festuccia, C.; Vicentini, C. Finasteride dose-dependently
reduces the proliferation rate of the LNCaP human prostatic cancer cell line in vitro. Urology
1995, 45, 282–290.
14. Kurup, A.; Garg, R.; Hansch, C. Comparative QSAR analysis of 5α-reductase inhibitors. Chem.
Rev. 2000, 100, 909–924.
15. Sudduth, S.L.; Koronkowski, M.J. Finasteride The first 5 alpha-reductase inhibitor.
Pharmacotherapy 1993, 309–325.
16. Lazier, C.B.; Thomas, L.N.; Douglas, R.C.; Vessey, J.P.; Rittmaster, R.S. Dutasteride, the dual 5
α-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate
cancer cell line. Prostate 2004, 58, 130–144.

Molecules 2009, 14
4668
17. McCrohan, A.M.; Morrissey, C.; O’Keane, C.; Mulligan, N.; Watson, C.; Smith, J.; Fitzpatrick,
J.M.; Watson, R.W. Effects of the dual 5 -reductase inhibitor dutasteride on apoptosis in primary
cultures of prostate cancer epithelial cells and cell lines. Cancer 2006, 106, 2743–2752.
18. Ling, Y.; Li, J.; Liu, Y.; Wang, X.; Klus, G.T.; Marat, K.; Nnane, I.P.; Brodie, A.M.H. Synthesis
and in vivo acting of some epimeric 20α-hydroxy, 20-oxime and aziridine pregnene derivatives as
inhibitors of human 17α-hydroxylase/C17,20-lyase and 5α-reductase. Bioorg. Med. Chem. 1998,
6, 1683–1693.
19. Victor, P.O.; Cabeza, M.; Bratoeff, E.; Heuze, I.; Sanchez, M.; Ramirez, E.; Elia, N.R. New 5-
reductase inhibitors: In vitro and in vivo effects. Steroids 2005, 70, 217–224.
20. Cruz-Silva, M.M.; Riva, S.; Sáe-Melo, M.L. Highly selective lipase-mediated diastereomeric 5,6-
epoxysteroids. Tetrahedron Asymmetry 2004, 15, 1173–1179.
21. Ma, E.; Kim, E. Epoxidation and reduction of DHEA, 1,4,6-androstatrien-3-one and 4,6-
androstadiene-3β,17β-diol. Molecules 2005, 10, 572–582.
22. Jang, S.; Lee, Y.; Hwang, S.L.; Lee, M.H.; Park, S.J.; Lee, I.H.; Kang, S.; Roh, S.S.; Seo, Y.J.;
Park, J.K.; Lee, J.H.; Lim, C.D. Establishment of type II 5α-reductase over-expressing cell line as
an inhibitor screening model. J. Steroid Biochem. Mol. Biol. 2007, 107, 245–252.
23. Smith, H.E.; Smith, R.G.; Toft, D.O.; Neergaaed, J.R.; Burrows, E.P.; O’Malley, B.W. Binding of
steroids to progesterone receptor proteins in chick oviduct and human uterus. J. Biol. Chem. 1974,
249, 5924–5932.
Sample Availability: Samples of the compounds are available from the authors.
© 2009 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland.
This article is an open-access article distributed under the terms and conditions of the Creative
Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).